Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Mar-Apr;72(2):65-69.
doi: 10.1016/j.ihj.2020.03.015. Epub 2020 Apr 8.

Expanding statin use for prevention of ASCVD in Indians: Reasoned and simplified proposals

Enas A Enas  1 , Basil Varkey  2 , Rajeev Gupta  3
Affiliations
Editorial

Expanding statin use for prevention of ASCVD in Indians: Reasoned and simplified proposals

Enas A Enas et al. Indian Heart J. 2020 Mar-Apr.

Abstract

Atherosclerosis, a systemic disease, is the predominant cause of cardiovascular disease (CVD) that far exceeds other causes (egs: congenital, hypertension, arrhythmia). CVD is the leading cause of mortality globally (18 million lives, including 9 million from coronary artery disease (CAD) annually).1 The Global Burden of Disease study reported that in the year 2017, India had one of the highest mortality, most of them premature, from CVD (2.64 million, women 1.18, men 1.45) and CAD (1.54 million, women 0.62, men 0.92) in the world.2 A systemic disease of this magnitude and impact warrants a proactive preventive strategy and not a reactive, invasive and focal approach. In this editorial, we call for a wider use of statins in Indians, explain our rationale based on risk factors and risk-enhancing factors, and present a simplified and cost effective approach to combat CVD.

Keywords: Atherosclerotic cardiovascular disease (ASCVD); Cholesterol; High-intensity therapy; Indians; Moderate-intensity therapy; Risk classification; Risk factors; Risk-enhancing factors; Statins.

PubMed Disclaimer

References

    1. Roth G.A., Johnson C., Abajobir A. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1–25. - PMC - PubMed
    1. Global health data exchange Available at: http://ghdx.healthdata.org/gbd-results-tool. accessed on April 20, 2020.
    1. Grundy S.M., Stone N.J., Bailey A.L. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American heart association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2018;73(24):3168–3209. - PubMed
    1. Mach F., Baigent C., Catapano A.L. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019;41(1):111–188. - PubMed
    1. Goldstein J.L., Brown M.S. A century of cholesterol and coronaries: from plaques to genes to statins. Cell. 2015;161(1):161–172. - PMC - PubMed

Publication types

Substances